trending Market Intelligence /marketintelligence/en/news-insights/trending/hnS4dC-ITdLNQ6d37B8AYQ2 content esgSubNav
In This List

Cerecor sells depression drug to Janssen Pharmaceuticals

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Cerecor sells depression drug to Janssen Pharmaceuticals

Cerecor Inc. sold all rights for CERC-501 to Johnson & Johnson's Janssen Pharmaceuticals Inc. for initial gross proceeds of $25 million.

Of the gross proceeds, $3.75 million was deposited into a 12-month escrow to secure future indemnification obligations to Janssen, as well as a potential future $20 million regulatory milestone payment.

CERC-501 is an oral kappa opioid receptor antagonist being developed to treat major depressive disorder and substance use disorders.

Janssen Pharmaceuticals will now be responsible for the drug's ongoing clinical trials as well as new development and commercialization.